Skip to Content

New Tendencies in Development of ALK-TKIs for Treatment of ALK-Rearranged NSCLC

ALK-rearrangements are oncogenic drivers in 3-5% of NSCLC and various cancers. Today, six TKI inhibitors are available for patients with advanced ALK-rearranged non-small cell lung cancer. In this MEDtalk, Edyta Maria Urbanska, Rigshospitalet, Copenhagen, Denmark, gives an overview of new tendencies in the development of ALK-TKIs.

Edyta Maria Urbanska

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top